Boston University & Med-IQ: BCMA-Directed Bispecific Antibodies in Multiple Myeloma: Mechanisms of Action, Clinical Efficacy, and Emerging Therapeutics
Expert faculty dive into the rapidly evolving world of BCMA-directed bispecific antibodies for multiple myeloma, exploring practical strategies to bring these cutting-edge therapies into everyday clinical care.
This series was developed by Boston University Chobanian & Avedisian School of Medicine in collaboration with the American Academy of Physician Associates, the Association of PAs in Oncology, HealthTree Foundation, and Med-IQ.
Cost: Free
View Offer chevron_rightKey Features
Safety and efficacy of BCMA-directed bispecific antibodies for the treatment of multiple myeloma
Topics Covered
BCMA-directed bispecific antibodies for the treatment of multiple myeloma
Learning Objectives
1. Explain the mechanism of action of BCMA-directed BsAbs
2. Characterize the safety and efficacy of BCMA-directed BsAbs for the treatment of MM
3. Appropriately incorporate BCMA-directed BsAbs into cases of patients with MM that are representative of clinical practice
Target Audience
This program is intended for oncologists, hematologists, physician associates, nurse practitioners, nurses, nurse navigators, pharmacists, and other healthcare professionals responsible for the care and treatment of people living with RRMM.
Additional credit info
This activity is developed as a joint collaboration among Boston University Chobanian & Avedisian School of Medicine, Med-IQ, the AAPA, the Association of PAs in Oncology (APAO), and HealthTree Foundation.
In support of improving patient care, Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Boston University Chobanian & Avedisian School of Medicine designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine Maintenance of Certification (MOC) Part 2 Credit. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
By participating and claiming credit, you agree to BU sharing your information with ACCME PARS the data conduit to the ABIM.
This activity is approved for 0.25 CPE credit. UAN is: JA0000185-9999-25-043-H01-P.
Nursing Contact Hours: 0.25, of which none are eligible for pharmacology credit.
Boston University Chobanian & Avedisian School of Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.